Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting

   Amgen And AstraZeneca Highlight Data To Be Presented At European League
                      Against Rheumatism Annual Meeting

PR Newswire

THOUSAND OAKS, Calif. and GAITHERSBURG, Md., June 12, 2013

THOUSAND OAKS, Calif. and GAITHERSBURG, Md., June 12, 2013 /PRNewswire/ --
Amgen (NASDAQ:AMGN) and AstraZeneca (AZN), with its biologics research and
development arm MedImmune, today announced that they will present data from a
Phase 2 study evaluating brodalumab, a human monoclonal antibody targeting the
IL-17 receptor, being investigated for the treatment of psoriatic arthritis at
the 2013 European League Against Rheumatism (EULAR) Annual Meeting
inMadrid,June 12-15, 2013.

"The brodalumab data being presented at EULAR demonstrate a positive
benefit-risk profile for patients with psoriatic arthritis," said Sean E.
Harper, M.D., executive vice president of Research and Development at Amgen.
"We are encouraged by these data as we continue to explore brodalumab for its
potential to treat patients with inflammatory disease including psoriatic
arthritis."

Based on the Phase 2 results, the companies intend to advance brodalumab into
Phase 3 clinical studies for the treatment of psoriatic arthritis in 2014.

"This brodalumab data marks a positive step forward for patients with
psoriatic arthritis," said Dr. Bahija Jallal, executive vice president,
MedImmune. "We look forward to working with Amgen to further evaluate this
novel therapy in psoriatic arthritis and potentially other chronic
immune-mediated diseases."

ABSTRACT OF INTEREST:

Brodalumab Abstract at EULAR:

  oEfficacy of Brodalumab, an Anti-IL-17R Antibody, in Subjects with
    Psoriatic Arthritis
    Abstract No. OP0103, Oral Presentation, Thursday, June 13, 10:20 a.m. CET,
    N117

Abstracts are currently available on the EULAR website at www.eular.org.

About Brodalumab

Brodalumab is a highly-selective human monoclonal antibody that binds to and
blocks signaling via the IL-17 receptor. The IL-17 pathway plays an important
role in inducing and promoting inflammatory disease processes.

Brodalumab is the first investigational treatment in development that blocks
the IL-17receptor, thereby blocking several of the IL-17 ligands at once. By
stopping IL-17 ligands from binding to the receptor, brodalumab prevents the
body from receiving signals that may lead to inflammation and other ailments.
At this time, other agents in development seek to target a single
IL-17ligand.

In addition to psoratic arthritis, brodalumab is currently being investigated
for the treatment of psoriasis (Phase 3) and asthma (Phase 2).

About Psoriatic Arthritis

Psoriatic arthritis is a chronic disease of the immune system that causes
joint pain, stiffness and swelling which can become progressively worse over
time, and may also include red patches of skin topped with silvery scales.^1

The progressive joint damage, pain and swelling coupled with painful, scaly,
red skin patches can disrupt a person's ability to perform daily activities,
such as using their hands, standing for long periods or walking.^2 Psoriatic
arthritis affects 30 to 50 percent^3 of the approximate 125 million people
worldwide who have psoriasis.^4

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping people around the world in the fight
against serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people's lives. For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com.

Amgen Forward-Looking Statements

This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results.Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission(SEC) reports filed
byAmgen, includingAmgen's most recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K.Please refer to Amgen's
most recent Forms 10-K, 10-Q and 8-K for additional information on the
uncertainties and risk factors related to our business. Unless otherwise
noted,Amgenis providing this information as ofJune 12, 2013,and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project.Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product.Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans.The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models.The length of time that it
takes for us to complete clinical trials and obtain regulatory approval for
product marketing has in the past varied and we expect similar variability in
the future. We develop product candidates internally and through licensing
collaborations, partnerships and joint ventures.Product candidates that are
derived from relationships may be subject to disputes between the parties or
may prove to be not as effective or as safe as we may have believed at the
time of entering into such relationship. Also, we or others could identify
safety, side effects or manufacturing problems with our products after they
are on the market.Our business may be impacted by government investigations,
litigation and product liability claims.If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the U.S.
government, we could become subject to significant sanctions. We depend on
third parties for a significant portion of our manufacturing capacity for the
supply of certain of our current and future products and limits on supply may
constrain sales of certain of our current products and product candidate
development.

In addition, sales of our products are affected by the reimbursement policies
imposed by third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed
care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement.Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products.We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products.In
addition, while we routinely obtain patents for our products and technology,
the protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates.We cannot guarantee that we will be able to
produce commercially successful products or maintain the commercial success of
our existing products.Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of our
products or product candidates.Further, the discovery of significant problems
with a product similar to one of our products that implicate an entire class
of products could have a material adverse effect on sales of the affected
products and on our business and results of operations.

The scientific information discussed in this news release related to our
product candidate is preliminary and investigative.Such product candidate is
not approved by theU.S. Food and Drug Administration (FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidate.Only theFDAcan determine whether the product
candidate is safe and effective for the use(s) being investigated.
Healthcareprofessionals shouldrefer to and rely upon theFDA-approved
labeling for the products, and not the information discussed in this news
release.

CONTACT:

                                      MedImmune/AstraZeneca
Amgen, Thousand Oaks
                                      Tracy Rossin, 301-398-1468 (media)
Ashleigh Koss, 805-313-6151 (media)
                                      Karl Hard +44 20-7604-8123 (investors)
Arvind Sood, 805-447-1060 (investors)
                                      Colleen Proctor 302-886-1842 (investors)

                                      Ed Seage 302-886-4065 (investors)

References

^1Krueger, Gerald G., MD. Clinical Features of Psoriatic Arthritis. The
American Journal of Managed Care. 2002; 8:160-170
^2Krueger G, Koo J, Lebwohl M, et al. The Impact of Psoriasis on Quality of
Life: Results of a 1998 National Psoriasis Foundation Patient-Membership
Survey. Arch Dermatol. 2001; 137:280-4
^3International Federation of Psoriasis Associations, Important facts about
psoriasis http://www.ifpa-pso.org/web/page.aspx?refid=47
^4About Psoriasis: Statistics. National Psoriasis Foundation.
http://www.psoriasis.org/learn_statistics

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(Logo: http://photos.prnewswire.com/prnh/20120329/LA79025LOGO)

SOURCE Amgen

Website: http://www.amgen.com
 
Press spacebar to pause and continue. Press esc to stop.